Efficient topical delivery of plasmid DNA to lung in vivo mediated by putative triggered, PEGylated pDNA nanoparticles

Aissaoui, Abderrahim; Chami, Mohamed; Hussein, M. Abid; Miller, Andrew D.

doi:10.1016/j.jconrel.2011.06.017

Cited by 28 publications

(25 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…172 Miller's team also showed that AB lipoplexes of DODAG 83a/DOPE at 1/1 molar ratio were shown to be efficacious in expressing pDNA (pCH-9/3091 expressing β-galactosidase) into HeLa, A549 and IB-3 cell lines, while ABC nanoparticles formulated from DODAG 83a/DOPE/PEG 4600 -Chol 90 at 43/43/14 molar ratio and lipid/pDNA weight ratio of 4 were able to transfect lung airways in a BALB/c murine model. 173 Recently, the same group showed that siRNA-ABC systems containing DODAG 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 …”

Section: Cholesteryl Cationic and Procationic Lipids In Nucleic Acid mentioning

confidence: 99%

“…Mention must be made that DODAG 83a/DOPE-pDNA lipoplexes were formulated with PEG 4600 -Chol 90 in order to make the lipoplexes stable enough to resist in lung mucus and to avoid mucocilliary clearance mechanisms. 173 (Entry 3 of Table S1) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 84 When i.v. delivery was used to target lungs, successful nanoparticles contained either simple formulations based on lipids BCAT 38, BSV4 60f or BSV18 60g and pDNA at +/-charge ratios between 4 and 6, 102,127,130 or complex formulations using both cationic lipids and colipids such as 47a/Chol/DNA at a +/-charge ratio of 2.…”

Section: In Vitro/in Vivo Translation For Dna Deliverymentioning

confidence: 99%

See 1 more Smart Citation

Synthetic Nucleic Acid Delivery Systems: Present and Perspectives

Draghici

Ilies

2015

J. Med. Chem.

View full text Add to dashboard Cite

Self-assembled synthetic gene delivery systems represent the bottom-up approach to gene delivery and gene silencing, in which scientists are designing novel cationic and procationic amphiphiles that can pack, transport, and deliver nucleic acids to various targets in the body in a controlled manner. These supramolecular assemblies are safer than viruses, but they are lagging behind them in efficiency. We are presenting recent progress that has narrowed this gap through better understanding the delivery barriers and incorporation of this knowledge in the design of novel synthetic amphiphiles, formulations, and revolutionary screening and optimization processes. Structure-properties and structure-activity relationships were drawn within each amphiphile class, presenting the cellular and animal models used to generate them. We are also revealing pertinent in vitro/in vivo correlations that emphasize promising amphiphiles and successful formulation optimization efforts for efficient in vivo nucleic acid delivery, together with main organ targets and diseases treatable with these revolutionary technologies.

show abstract

Section: Cholesteryl Cationic and Procationic Lipids In Nucleic Acid mentioning

confidence: 99%

Section: In Vitro/in Vivo Translation For Dna Deliverymentioning

confidence: 99%

Synthetic Nucleic Acid Delivery Systems: Present and Perspectives

Draghici

Ilies

2015

J. Med. Chem.

View full text Add to dashboard Cite

show abstract

“…In more recent times, prototype nucleic acid-AB, -ABC, or -ABCD nanoparticles have been tested for functional delivery of therapeutic nucleic acids to target cells in animal models of human disease (to liver for treatment of hepatitis B and C virus infection, to ovarian cancer lesions for cancer therapy) and to target cells in murine lungs [42–47]. Rules for enhancing efficient delivery through receptor-mediated uptake of nucleic acid-ABCD nanoparticles into target cells are also being studied and appreciated [48–50] (Wang, M. et al, J.…”

Section: Prototype Drug Nanoparticles For Cancer Therapymentioning

confidence: 99%

“…Such nanoparticles are designed for high levels of stability in biological fluid from points of administration to target cells whereupon they become triggered for the controlled release of therapeutic agent payload(s) by changes in local endogenous conditions (such as in pH, t 1/2 , enzyme, redox state, and temperature status), [42–46, 65] or through application of an external/exogenous stimulus (Wright M. et al, 2013, papers in preparation and submission). While much of previous work on this topic has revolved around change(s) in local endogenous conditions [42–46, 65], the development of appropriate exogenous stimuli looks to be a real growth area for the future. In principle, all ABC/ABCD nanoparticles could be triggered to exhibit physical property change(s) through interaction with light, ultrasound, radiofrequency, and thermal radiation from defined sources.…”

Section: Next Generation Lnps For Cancer Imaging and Therapymentioning

confidence: 99%

Lipid-Based Nanoparticles in Cancer Diagnosis and Therapy

Miller

2013

Journal of Drug Delivery

Self Cite

View full text Add to dashboard Cite

Today, researchers are constantly developing new nanomaterials, nanodevices, and nanoparticles to meet unmet needs in the delivery of therapeutic agents and imaging agents for cancer therapy and diagnosis, respectively. Of particular interest here are lipid-based nanoparticles (LNPs) that are genuine particles (approximately 100 nm in dimension) assembled from varieties of lipid and other chemical components that act collectively to overcome biological barriers (biobarriers), in order for LNPs to preferentially accumulate in or around disease-target cells for the functional delivery of therapeutic agents for treatment or of imaging agents for diagnosis. The capabilities of these LNPs will clearly vary depending on functional requirements, but the nanoscale allows for an impressive level of diversity in capabilities to enable corresponding LNPs to address an equally diverse range of functional requirements. Accordingly, LNPs should be considered appropriate vehicles to provide an integrated, personalized approach to cancer diagnosis and therapy in future cancer disease management.

show abstract

“…For example, DNA loaded lipid NPs shows mediated transfection in vivo and tends to target the epithelial cells of bronchii and bronchioli airway passages [105]. These particles could be used in treatment for viral infection and cystic fibrosis.…”

Section: Therapeutic Applicationsmentioning

confidence: 99%

Nanomaterials for Management of Lung Disorders and Drug Delivery

Menon¹,

Wadajkar²,

Xie³

et al. 2013

Nanomaterials in Drug Delivery, Imaging, and Tissue Engineering

View full text Add to dashboard Cite

There has been an increasing interest in pulmonary drug delivery and lung tissue regeneration to treat lung disorders in the past two decades. This route of administration is advantageous for both systemic as well as local drug delivery due to the large surface area available in the lung for drug absorption, higher permeability to solutes, and the noninvasive nature of treatment. Inhalational drug delivery is also highly beneficial for the diagnosis and treatment of lung diseases such as pulmonary arterial hypertension, cystic fibrosis, asthma, and lung cancer. Statistics show that lung cancer alone is responsible for nearly 1.3 million deaths worldwide every year, necessitating the need for alternative treatment methods, which can cure the disease while reducing discomfort to the patient. This chapter attempts to summarize the different types of nanoparticles (NPs) currently available for pulmonary drug delivery, the various targeting mechanisms for drug delivery and uptake, the applications of these NPs, and the current challenges faced in inhalational drug delivery. Further, the lung half-life of the NPs and their clearance rate from the lung following administration will also be discussed.

show abstract

Efficient topical delivery of plasmid DNA to lung in vivo mediated by putative triggered, PEGylated pDNA nanoparticles

Cited by 28 publications

References 54 publications

Synthetic Nucleic Acid Delivery Systems: Present and Perspectives

Synthetic Nucleic Acid Delivery Systems: Present and Perspectives

Lipid-Based Nanoparticles in Cancer Diagnosis and Therapy

Nanomaterials for Management of Lung Disorders and Drug Delivery

Contact Info

Product

Resources

About